RxDoctor Payments Data

Chris Chung, MD

Sports Medicine · Santa Clara, CANPI 1528043403

Payments from drug & device makers

$517in general payments, 2019–2025

Across 7 payments — averaging $73.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$224
  • Glaukos Corporation$140
  • Medtronic$102
  • Bioventus LLC$19
  • Novo Nordisk$17
  • Sanofi-aventis U.S. LLC$14

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517 in reported general payments places this provider in the 35th percentile of 662 sports medicine providers in California.

See all sports medicine providers in California

Medicare billing

Part B allowed, 2024
$125,302
Medicare patients
366
Services billed
5,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$22,186
EliquisApixaban26$20,941
JanuviaSitagliptin Phosphate27$14,963
FarxigaDapagliflozin Propanediol17$12,432
Levothyroxine Sodium205$2,780
SynthroidLevothyroxine Sodium36$2,630
Atorvastatin Calcium201$2,066
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$1,983
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,945
Pantoprazole Sodium79$1,747
Divalproex Sodium12$1,452
Simvastatin119$1,290
Losartan Potassium141$1,284
Tamsulosin Hcl68$1,095
Gabapentin68$1,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$22,18618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 662 sports medicine providers in California.

Other sports medicine in Santa Clara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →